Our findings reveal a previously unrecognized link between GPR44 signaling, selenium metabolism, and leukemia progression, warranting further studies to explore selenoprotein-targeting strategies for AML treatment. The gene discussed is PTGDR2; the disease is acute myeloid leukemia.